DUBLIN, Nov 15, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Actinic Keratosis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2012 To 2022" report to their offering.
Actinic keratosis (AK) is portrayed by skin papules, macules or plaques coming about because of delayed presentation to hurtful UV introduction and can bring about squamous cell carcinoma.
Among the different treatment strategies accessible, ruinous treatments, for example, fluid nitrogen cryotherapy and surgical treatment constitute the highest quality level for AK treatment. In 2015, cryotherapy was the most ordinarily looked for treatment by clinicians. Notwithstanding, better clinical consequences of photodynamic treatment and developing inclination for medications in view of medication gadget mix have asked both parental figures and patients to choose novel treatment techniques that offer both propelled adequacy, stylish advantages and decreased danger of future malignancies.
Topical treatment is a delayed treatment and nearly more compelling than different medications yet tolerant consistence is the key issue that ruins the development of this fragment. Photodynamic treatment is the quickest developing treatment all through the gauge time frame because of rising interest for non-obtrusive surgeries, and less treatment sessions are the key variables anticipated that would help this market
North America is the biggest market for actinic keratosis treatment because of developing predominance of AK, better open mindfulness about event of AK and related danger of squamous cell carcinoma. As per American Academy of Dermatology (AAD), around 60% of the Americans matured 40 year or above, Actinic Keratosis is inclined to create having no less than 1 AK injury. Actinic keratosis is antecedents of squamous cell disease. U.S. held the biggest partake in the actinic keratosis market in 2015 attributable to current commonness of actinic keratosis in the region.
Asia Pacific is the quickest developing market for AK medicines. Australia has the most astounding pervasiveness of actinic keratosis going between 40% to 60% in grown-up populace. Developing mindfulness in the area and fast improvement in social insurance framework and human services use are the key development figures Asia Pacific actinic keratosis market.
- Apotex, Inc.
- Aqua Pharmaceuticals, Llc
- Dusa Pharmaceuticals, Inc. (Sun Pharma)
- Galderma S.A.
- Leo Laboratories Ltd. (Leo Pharma A/S)
- Perrigo Company Plc,
- Tolmar Pharmaceuticals, Inc.
- Valeant Pharmaceuticals International, Inc.
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Market Overview
Chapter 4 Global Actinic Keratosis Market, By Treatments
Chapter 5 Global Actinic Keratosis Market, By Geography
Chapter 6 Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/s6s9sg/global_actinic
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-actinic-keratosis-market-analysis---trends-technologies--opportunities-report-2012-2022---vendors-galderma-valeant-pharma-dusa-pharma-300363363.html
SOURCE Research and Markets